Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

Allan Lipton, Harold Harvey, R. J. Santen, A. Boucher, D. White, A. Bernath, R. Dixon, G. Richards, A. Shafik

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


We compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide-hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Fifteen of 39 patients (38%) who received tamoxifen experienced an objective tumor regression (3 complete, 12 partial remissions), whereas 13 of 36 women (36%) receiving aminoglutethimide responded (one complete remission, 12 partial remissions). The median duration of response was similar. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

Original languageEnglish (US)
Pages (from-to)3434s-3436s
JournalCancer Research
Issue number8 Suppl.
StatePublished - 1982

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this